IMAGENE trial: Multicenter, proof-of-concept, phase II study evaluating the efcacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
Số trang: 6
Loại file: pdf
Dung lượng: 827.76 KB
Lượt xem: 11
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Previous clinical trials have demonstrated the potential efcacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients with cancer involving homologous recombination repair (HRR) gene-mutation. Moreover, HRR gene-mutated cancers are effectively treated with immune checkpoint inhibitors (ICIs) with the increase in tumor mutation burden.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Previous clinical trials Potential efcacy ADP-ribose Homologous recombination repair Gene-mutationGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 117 0 0 -
12 trang 92 0 0
-
19 trang 74 0 0
-
17 trang 62 0 0
-
9 trang 40 0 0
-
12 trang 37 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0